Fremanezumab-VFRM Drug Asset Due Diligence Report 2026

This Fremanezumab-VFRM Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Approved

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: GO

Decision memo

Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.

The central underwriting question is whether Fremanezumab-VFRM can convert its Monoclonal antibody profile and CGRP biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Fremanezumab-VFRM (query alias: fremanezumab)
Modality / target	Monoclonal antibody; CGRP; CGRP antagonists
Highest global status	Approved
Originator	Teva Pharmaceuticals USA, Inc.
Active developers	Vetter Pharma-Fertigung GmbH & Co. KG, Teva Pharmaceuticals Australia Pty Ltd, Teva Pharmaceuticals USA, Inc.

The MCP disease footprint includes Migraine Disorders. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT07653516	Phase 4	Not yet recruiting	30	Severity of acute mountain sickness as measured by the Lake Louise Score (LLS)
NCT07029126	Not Applicable	Recruiting	300	CHANGE in caregiver stress
NCT06659120	Not Applicable	Recruiting	120	Change of migraine days per month

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety, and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Chronic Migraine in Pediatric Patients 6 to 17 Years of Age

Phase 3; n=292; evaluation: not stated. Reported fields: Mean Change From Baseline in Monthly Average Number of Migraine Days During 12-Week Period After the First Dose of Study Drug(Least Squares Mean) = -3.7 days/month (Standard Error, 0.78); Mean Change From Baseline in Monthly Average Number of Migraine Days During 12-Week Period After the First Dose of Study Drug(Least Squares Mean): LS Mean Difference = -0.1(95% CI, -1.48 to 1.22), P-Value = 0.8484; Mean Change From Baseline in Monthly Average Number of Migraine Days During 12-Week Period After the First Dose of Study Drug(Least Squares Mean): LS Mean Difference = -0.1(95% CI, -1.48 to 1.22), P-Value = 0.8484

Fremanezumab for the Treatment of Patients With Migraine and Comorbid Major Depressive Disorder

Phase 4; n=540; evaluation: Positive. Reported fields: MMD(12-week) = -2.9 Day (95%CI, -3.89 to -1.96); MMD(12-week) = -5.1 Day (95%CI, -6.09 to -4.13)

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety, and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Episodic Migraine in Pediatric Patients 6 to 17 Years of Age

Phase 3; n=235; evaluation: not stated. Reported fields: Mean Change From Baseline in Monthly Average Number of Migraine Days During 12-Week Period After the First Dose of Study Drug(Least Squares Mean) = -1.4 days/month (Standard Error, 0.39); Mean Change From Baseline in Monthly Average Number of Migraine Days During 12-Week Period After the First Dose of Study Drug(Least Squares Mean): LS mean Difference = -1.0(95% CI, -1.90 to -0.16), P-Value = 0.0210; Mean Change From Baseline in Monthly Average Number of Migraine Days During 12-Week Period After the First Dose of Study Drug(Least Squares Mean): LS mean Difference = -1.0(95% CI, -1.90 to -0.16), P-Value = 0.0210

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Fremanezumab-VFRM addresses Migraine Disorders. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Monoclonal antibody—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 6 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2026-04-22	Biopharmaceutical Company Teva to Bring Innovative Migraine Treatment to China With NeuroGen Pharma	Approved	Financial terms not disclosed
2026-01-07	Hanmi Pharmaceutical to sell migraine prevention drug Ajovy in Korea	Approved	Financial terms not disclosed
2023-11-06	梯瓦与华润广东医药达成战略合作，加速推动大湾区偏头痛患者用药可及	Approved	Financial terms not disclosed

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Treatment of headache disorders and/or psychiatric symptoms using Anti-CGRP antibodies, and compositions and methods related thereto”. The milestone feed surfaced a patent-application signal described as “Methods for treating calcitonin gene-related peptide (CGRP) - expressing cancers”. The milestone feed surfaced a patent-application signal described as “CGRP/RAMP1 blockade to treat endometriosis-associated pain and reduce endometriosis lesions”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Class crowding and differentiation versus other PD-(L)1/VEGF agents
Immune and anti-angiogenic safety, including bleeding and cardiovascular risk
Biomarker strategy, indication selection, and head-to-head endpoint execution

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

GO